AU2007322217A1 - Methods of promoting cardiac repair using growth factors fused to heparin binding sequences - Google Patents

Methods of promoting cardiac repair using growth factors fused to heparin binding sequences Download PDF

Info

Publication number
AU2007322217A1
AU2007322217A1 AU2007322217A AU2007322217A AU2007322217A1 AU 2007322217 A1 AU2007322217 A1 AU 2007322217A1 AU 2007322217 A AU2007322217 A AU 2007322217A AU 2007322217 A AU2007322217 A AU 2007322217A AU 2007322217 A1 AU2007322217 A1 AU 2007322217A1
Authority
AU
Australia
Prior art keywords
seq
lys
gly
arg
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007322217A
Other languages
English (en)
Inventor
Richard Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The Brigham and Women's Hospital Inc
Original Assignee
The Brigham and Women's Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Brigham and Women's Hospital Inc filed Critical The Brigham and Women's Hospital Inc
Publication of AU2007322217A1 publication Critical patent/AU2007322217A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AU2007322217A 2006-11-13 2007-11-08 Methods of promoting cardiac repair using growth factors fused to heparin binding sequences Abandoned AU2007322217A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US85840606P 2006-11-13 2006-11-13
US60/858,406 2006-11-13
US11/979,708 2007-11-07
US11/979,708 US9187517B2 (en) 2006-11-13 2007-11-07 Methods of promoting cardiac repair using growth factors fused to heparin binding sequences
PCT/US2007/023527 WO2008063424A2 (en) 2006-11-13 2007-11-08 Methods of promoting cardiac repair using growth factors fused to heparin binding sequences

Publications (1)

Publication Number Publication Date
AU2007322217A1 true AU2007322217A1 (en) 2008-05-29

Family

ID=39430287

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007322217A Abandoned AU2007322217A1 (en) 2006-11-13 2007-11-08 Methods of promoting cardiac repair using growth factors fused to heparin binding sequences

Country Status (13)

Country Link
US (2) US9187517B2 (enExample)
EP (1) EP2091550B1 (enExample)
JP (1) JP2010508845A (enExample)
KR (1) KR20090087061A (enExample)
AU (1) AU2007322217A1 (enExample)
BR (1) BRPI0718679A2 (enExample)
CA (1) CA2670830A1 (enExample)
IL (1) IL198708A0 (enExample)
MX (1) MX2009005090A (enExample)
NO (1) NO20092261L (enExample)
NZ (1) NZ577235A (enExample)
RU (1) RU2009122456A (enExample)
WO (1) WO2008063424A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187517B2 (en) * 2006-11-13 2015-11-17 The Brigham And Women's Hospital, Inc. Methods of promoting cardiac repair using growth factors fused to heparin binding sequences
US8691771B2 (en) * 2010-05-21 2014-04-08 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins for tissue repair
JP2012093290A (ja) * 2010-10-28 2012-05-17 Sumitomo Bakelite Co Ltd 医療用粒子および生理活性物質の捕捉方法
US9421245B2 (en) * 2012-06-25 2016-08-23 The Brigham And Women's Hospital, Inc. Targeted therapeutics
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
WO2014004467A1 (en) * 2012-06-25 2014-01-03 The Brigham And Women's Hospital, Inc. Selective cartilage therapy
CA3000742A1 (en) 2015-10-02 2017-04-06 Silver Creek Pharmaceuticals, Inc. Bi-specific therapeutic proteins for tissue repair
EA037848B1 (ru) * 2016-07-14 2021-05-27 Общество С Ограниченной Ответственностью "Биохимический Агент" Гибридный белок, полинуклеотид, генетическая конструкция, продуцент, препарат для регенерации хряща (варианты)
JP2021516966A (ja) 2018-03-09 2021-07-15 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 組織への生物学的薬物の送達

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670483A (en) * 1992-12-28 1997-09-23 Massachusetts Insititute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
US6037329A (en) * 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
US5723331A (en) * 1994-05-05 1998-03-03 Genzyme Corporation Methods and compositions for the repair of articular cartilage defects in mammals
EP0920490A2 (en) * 1996-07-25 1999-06-09 Genzyme Corporation Chondrocyte media formulations and culture procedures
AUPP298498A0 (en) * 1998-04-17 1998-05-07 Gropep Pty Ltd Matrix binding factor
AU2001288392A1 (en) * 2000-08-30 2002-03-13 University Of Delaware Delivery system for heparin-binding growth factors
CA2496732A1 (en) 2002-08-20 2004-03-04 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
US7166574B2 (en) * 2002-08-20 2007-01-23 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
US7598224B2 (en) * 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
WO2005014619A2 (en) * 2003-03-28 2005-02-17 Thomas Jefferson University Heparin-binding peptides and uses thereof
US20080227696A1 (en) * 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
US7399831B2 (en) * 2004-10-25 2008-07-15 The Brigham And Women's Hospital, Inc. Targeted delivery of biological factors using self-assembling peptide nanofibers
AU2005323062A1 (en) * 2005-01-04 2006-07-13 The Brigham And Women's Hospital, Inc. Sustained delivery of PDGF using self-assembling peptide nanofibers
US9187517B2 (en) * 2006-11-13 2015-11-17 The Brigham And Women's Hospital, Inc. Methods of promoting cardiac repair using growth factors fused to heparin binding sequences

Also Published As

Publication number Publication date
US20080138323A1 (en) 2008-06-12
IL198708A0 (en) 2011-08-01
US20160024170A1 (en) 2016-01-28
JP2010508845A (ja) 2010-03-25
MX2009005090A (es) 2009-07-24
KR20090087061A (ko) 2009-08-14
NO20092261L (no) 2009-08-06
EP2091550A4 (en) 2009-12-09
WO2008063424A3 (en) 2008-09-12
US9187517B2 (en) 2015-11-17
EP2091550B1 (en) 2013-01-02
RU2009122456A (ru) 2010-12-20
EP2091550A2 (en) 2009-08-26
WO2008063424A2 (en) 2008-05-29
US9969788B2 (en) 2018-05-15
BRPI0718679A2 (pt) 2014-02-04
NZ577235A (en) 2011-12-22
CA2670830A1 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
US9969788B2 (en) Methods of treating damaged cartilage tissue using growth factors fused to heparin binding sequences
JP2010508845A5 (enExample)
King et al. Direct demonstration of separate receptors for growth and metabolic activities of insulin and multiplication-stimulating activity (an insulinlike growth factor) using antibodies to the insulin receptor
JP5993827B2 (ja) ミオスタチンアンタゴニスト
McLane et al. Disintegrins in health and disease
Smith Somatomedin carrier proteins
Tokunou et al. Engineering insulin-like growth factor-1 for local delivery
WO1999022756A1 (en) Cell-permeable protein inhibitors of calpain
Swope et al. Bombesin stimulates insulin secretion by a pancreatic islet cell line.
CN1774448B (zh) 生长因子复合物及细胞迁移和生长的调节
CA2233009C (en) Composition for improving pancreatic function
CA2821715A1 (en) Chimeric fibronectin matrix mimetics and uses thereof
EP3980446A1 (en) Bioactive agents and methods related thereto
CN103694340B (zh) 重组蛋白igf1-24及其应用
WO1999054359A1 (en) Matrix binding factor
JP3945846B2 (ja) 膵臓機能改善剤
US20090269848A1 (en) Technique for culture of mesenchymal stem cell utilizing laminin-5
CN101300269A (zh) 机械生长因子肽及其用途
CN101547704A (zh) 使用融合至肝素结合序列的生长因子促进心脏修复的方法
AU2003287289B2 (en) Promotion of peroxisomal catalase function in cells
CN101291955A (zh) 具有组织再生功能的未活化多肽及其制备方法
US20110092427A1 (en) Polypeptide and pharmaceutical composition containing the polypeptide
KR102877150B1 (ko) 연골 재생용 펩타이드 및 이의 용도
KR102913342B1 (ko) 연골 재생용 펩타이드 및 이의 용도
KR20170143216A (ko) Fndc5를 포함하는 융합 단백질 및 이의 용도

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application